India\'s First Alzheimer Therapy: Launch of Donanemab (Lormalzi)

• Groundbreaking Medical Milestone: India has received its first disease-modifying therapy for Alzheimer with the launch of the drug Donanemab under the brand name Lormalzi by pharmaceutical major Eli Lilly. 

• Mechanism of Action: Administered as a once-a-month 350 mg intravenous infusion, the drug works by dissolving amyloid beta protein plaques in the brain, which is a hallmark sign of the neuro-degenerative condition. 

• Clinical Efficacy and Limitations: Clinical trials indicate the drug can slow cognitive decline in early-stage patients by approximately 35.1% over 76 weeks; however, it cannot reverse damage that has already occurred. 

• Target Demographic: The therapy is strictly intended for patients in the early stages of Alzheimer—specifically those with mild cognitive impairment or mild dementia—and is not suitable for advanced cases. 

• Economic Barrier and Accessibility: Costing approximately Rs 1 lakh per dose (specifically Rs 91,688), the 18-month treatment course remains prohibitively expensive for most Indians, though the company plans an access programme for lower pricing. 

• Safety Concerns: The drug is associated with amyloid-related imaging abnormalities (ARIA), including brain swelling and bleeding, which affected a significant percentage of trial participants and resulted in three treatment-related deaths. 

Key Definitions 

• Alzheimer Disease: A progressive, neuro-degenerative condition characterized by the buildup of plaques in the brain, leading to memory loss and cognitive decline. 

• Monoclonal Antibody: Laboratory-made proteins designed to target specific substances in the body; in this case, they target and remove amyloid beta plaques from the brain. 

• Amyloid Beta Plaques: Protein fragments that clump together between nerve cells in the brain, disrupting communication and triggering immune responses that destroy cells. 

Constitutional and Legal Provisions 

• Article 21: The Right to Life and Personal Liberty, which the Supreme Court has interpreted to include the right to health and access to affordable medical treatment. 

• Article 47: A Directive Principle of State Policy (DPSP) that mandates the State to regard the improvement of public health as among its primary duties.

• Drugs and Cosmetics Act, 1940: The primary legislation regulating the import, manufacture, and distribution of drugs in India, ensuring safety and efficacy standards for new launches like Donanemab. 

• National Health Policy, 2017: Aims at attaining the highest possible level of health and wellbeing for all through a preventive and promotive health care orientation in all developmental policies. 

Healthcare Challenges in India 

• Rising Disease Burden: Dementia currently affects over 8.8 million people in India, a figure projected to nearly double to 16.9 million by 2036, with Alzheimer accounting for the majority of cases. 

• Diagnostic Gaps: The effectiveness of Donanemab relies heavily on early diagnosis, which is currently rare in India due to a lack of specialized screening infrastructure and public awareness. 

• Infrastructure Readiness: The Indian health system faces significant hurdles in managing specialized intravenous therapies that require continuous monitoring for side effects like brain swelling. 

Conclusion 

The introduction of Donanemab, as detailed in marks a significant shift from symptomatic management to disease-modifying intervention for Alzheimer in India. While the high cost and safety risks present immediate challenges, the arrival of such innovative therapies offers a glimmer of hope for millions. To truly benefit the population, the government and private sector must collaborate to improve early detection facilities and reduce the financial burden of specialized geriatric care. 

UPSC Relevance 

• GS Paper II: Issues relating to development and management of Social Sector/Services relating to Health; Government policies and interventions. 

• GS Paper III: Science and Technology- developments and their applications and effects in everyday life; Indigenization of technology and developing new technology. 

• Prelims: Understanding of neuro-degenerative diseases, monoclonal antibodies, and the role of the Central Drugs Standard Control Organisation (CDSCO).